ACE Inhibitors News and Research

RSS
ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.
Soligenix announces personalized medicine collaboration with SciClone

Soligenix announces personalized medicine collaboration with SciClone

Longer prescriptions after leaving hospital associated with long-term adherence in cardiac patients

Longer prescriptions after leaving hospital associated with long-term adherence in cardiac patients

Too much sugar can lead to heart failure, shows study

Too much sugar can lead to heart failure, shows study

New survey data reveal need for specialist nurse support in management of patients with heart failure

New survey data reveal need for specialist nurse support in management of patients with heart failure

Coenzyme Q10 decreases all cause mortality by half in randomized double blind trial

Coenzyme Q10 decreases all cause mortality by half in randomized double blind trial

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

Unavoidable damage to heart and lungs can be limited by using CVD drug

Unavoidable damage to heart and lungs can be limited by using CVD drug

Study finds no evidence that digoxin increases mortality in patients with atrial fibrillation

Study finds no evidence that digoxin increases mortality in patients with atrial fibrillation

L-carnitine improves cardiac health in patients after heart attack, say researchers

L-carnitine improves cardiac health in patients after heart attack, say researchers

Aliskiren and standard therapy not associated with reduced CV death or HF rehospitalization

Aliskiren and standard therapy not associated with reduced CV death or HF rehospitalization

African-American women with breast cancer more likely to develop heart failure

African-American women with breast cancer more likely to develop heart failure

New Orleans residents continue to face increased risk of heart attack post-Katrina

New Orleans residents continue to face increased risk of heart attack post-Katrina

Benefits of diastolic function improvement in heart failure questioned

Benefits of diastolic function improvement in heart failure questioned

Morning, smooth ambulatory BP control ‘rarely achieved’ in general practice

Morning, smooth ambulatory BP control ‘rarely achieved’ in general practice

Ramipril puts spring in step of patients with intermittent claudication

Ramipril puts spring in step of patients with intermittent claudication

Ramipril may improve pain-free walking among patients with PAD and intermittent claudication

Ramipril may improve pain-free walking among patients with PAD and intermittent claudication

Dual renin angiotensin system blockade: too many cons

Dual renin angiotensin system blockade: too many cons

Hydrogen sulfide may play a wide-ranging role in staving off aging

Hydrogen sulfide may play a wide-ranging role in staving off aging

German Research Foundation approves funding for Mainz study on cardiovascular disorders

German Research Foundation approves funding for Mainz study on cardiovascular disorders

Chronic heart failure treatment, Inspra (eplerenone), accepted for use within NHS Wales

Chronic heart failure treatment, Inspra (eplerenone), accepted for use within NHS Wales

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.